



Sutent® (sunitinib) – First-time generic

- On August 16, 2021, Sun launched an [AB-rated](#) generic version of Pfizer's [Sutent \(sunitinib\)](#) capsules.
- Sutent is approved to treat adult patients with gastrointestinal stromal tumor, advanced renal cell carcinoma, adjuvant treatment of renal cell carcinoma, and advanced pancreatic neuroendocrine tumors.
- Sutent carries a boxed warning for hepatotoxicity.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.